Generic placeholder image

Current Drug Therapy

Editor-in-Chief

ISSN (Print): 1574-8855
ISSN (Online): 2212-3903

Editorial

Optogenetics: A New Era of Novel Drug Delivery-based Approach for Neurodegeneration

Author(s): Dilpreet Singh*

Volume 19, Issue 3, 2024

Published on: 27 November, 2023

Page: [271 - 274] Pages: 4

DOI: 10.2174/0115748855274992231114051324

Next »
[1]
Deisseroth K. Optogenetics: 10 years of microbial opsins in neuroscience. Nat Neurosci 2015; 18(9): 1213-25.
[http://dx.doi.org/10.1038/nn.4091] [PMID: 26308982]
[2]
Boyden ES, Zhang F, Bamberg E, Nagel G, Deisseroth K. Millisecond-timescale, genetically targeted optical control of neural activity. Nat Neurosci 2005; 8(9): 1263-8.
[http://dx.doi.org/10.1038/nn1525] [PMID: 16116447]
[3]
Gradinaru V, Thompson KR, Zhang F, et al. Targeting and readout strategies for fast optical neural control in vitro and in vivo. J Neurosci 2007; 27(52): 14231-8.
[http://dx.doi.org/10.1523/JNEUROSCI.3578-07.2007] [PMID: 18160630]
[4]
Packer AM, Roska B, Häusser M. Targeting neurons and photons for optogenetics. Nat Neurosci 2013; 16(7): 805-15.
[http://dx.doi.org/10.1038/nn.3427] [PMID: 23799473]
[5]
Yizhar O, Fenno LE, Davidson TJ, Mogri M, Deisseroth K. Optogenetics in neural systems. Neuron 2011; 71(1): 9-34.
[http://dx.doi.org/10.1016/j.neuron.2011.06.004] [PMID: 21745635]
[6]
Diester I, Kaufman MT, Mogri M, et al. An optogenetic toolbox designed for primates. Nat Neurosci 2011; 14(3): 387-97.
[http://dx.doi.org/10.1038/nn.2749] [PMID: 21278729]
[7]
Ghanbari L, Bauer M, Neumann E, et al. Optogenetic modulation of neural circuits in cerebellar ataxia. Front Syst Neurosci 2018; 12: 31.
[8]
Airan RD, Thompson KR, Fenno LE, Bernstein H, Deisseroth K. Optogenetic control of drug delivery for neurodegenerative diseases. Front Neurosci 2023. Epub ahead of print
[9]
Liu X, Chen Y, Wang Z, et al. Recent advances in optogenetics for targeted drug delivery in neurodegenerative diseases. J Control Release 2022; 345: 112-25.
[10]
Zhang Q, Li W, Chen J, et al. Optogenetics-enhanced drug delivery systems for neurodegenerative diseases: Recent developments and future perspectives. Adv Drug Deliv Rev 2022; 187: 113-28.
[11]
Wang Y, Zhang L, Li H, et al. Optogenetic control of drug release for targeted treatment of neurodegenerative disorders. Biomaterials 2021; 269: 120641.
[12]
Patel S, Kapoor N, Eberhart R, et al. Optogenetics for precise drug delivery in neurodegenerative diseases: Current status and future directions. Front Bioeng Biotechnol 2021; 9: 720622.
[13]
Chuong AS, Miri ML, Busskamp V, et al. Noninvasive optical inhibition with a red-shifted microbial rhodopsin. Nat Neurosci 2014; 17(8): 1123-9.
[http://dx.doi.org/10.1038/nn.3752] [PMID: 24997763]
[14]
Bernstein JG, Han X, Henninger MA, et al. Prosthetic systems for therapeutic optical activation and silencing of genetically-targeted neurons. Proc Soc Photo Opt Instrum Eng 2009; 7169: 71690G.
[15]
Chen B, Cui M, Wang Y, Shi P, Wang H, Wang F. Recent advances in cellular optogenetics for photomedicine. Adv Drug Deliv Rev 2022; 188: 114457.
[http://dx.doi.org/10.1016/j.addr.2022.114457] [PMID: 35843507]
[16]
Hsieh FY, Han HW, Chen XR, Yang CS, Wei Y, Hsu S. Non-viral delivery of an optogenetic tool into cells with self-healing hydrogel. Biomaterials 2018; 174: 31-40.
[http://dx.doi.org/10.1016/j.biomaterials.2018.05.014] [PMID: 29777961]
[17]
Wu J, Cui X, Ke PC, et al. Nanomaterials as novel agents for amelioration of Parkinson’s disease. Nano Today 2021; 41: 101328.
[http://dx.doi.org/10.1016/j.nantod.2021.101328]
[18]
Navitsky C. Novel optogenetic therapy may restore vision after retinal degeneration. Retina Today 2012; (Apr): 14-5.
[19]
Shiri Z, Simorgh S, Naderi S, Baharvand H. Optogenetics in the era of cerebral organoids. Trends Biotechnol 2019; 37(12): 1282-94.
[http://dx.doi.org/10.1016/j.tibtech.2019.05.009] [PMID: 31227305]

© 2024 Bentham Science Publishers | Privacy Policy